The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share. The biotechnology company ...
News
- Regenxbio: 2Q Earnings Snapshot
- Acceleron: 2Q Earnings Snapshot
The clinical stage biotech developing protein therapeutics for cancer and rare diseases posted revenue of $39.8 million in the period, also topping ...
- Swiss ink deal with Moderna for 4.5M doses of COVID vaccine
... struck a deal with Moderna to supply Switzerland with 4.5 million doses of a COVID-19 vaccine if the U.S. biotech firm successfully develops one.
- Pfenex: 2Q Earnings Snapshot
The biotechnology company posted revenue of $781,000 in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $2.7 ...
- The Latest: Hong Kong offers free testing for all residents
... has struck a deal with Moderna to supply Switzerland with 4.5 million doses of COVID-19 vaccine if the U.S. biotech firm successfully develops one.